Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T12:05:43.090Z.
Calculation as of: 2026-10-06T12:05:43.090Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$288.39M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$291.25M
PS Ratio
11.41
TTM Avg
341.11
3Y Avg
260.22
5Y Avg
137.39
Market Cap
$264.10M
PS Ratio
94.69
TTM Avg
82.20
3Y Avg
35.74
5Y Avg
24.54
Market Cap
$317.09M
PS Ratio
N/A
TTM Avg
995.02
3Y Avg
3050.37
5Y Avg
3251.65
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $288.39M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $291.25M | 11.41 | 341.11 | 260.22 | 137.39 |
| Fate Therapeutics, Inc. (FATE)vs › | $283.24M | 43.64 | 30.89 | 23.00 | 28.64 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.06M | N/A | 6.36 | 62.99 | 58.72 |
| Aurora Cannabis Inc. (ACB)vs › | $276.26M | 1.33 | 0.91 | 1.11 | 1.80 |
| AC Immune S.A. (ACIU)vs › | $275.81M | 12.71 | 46.34 | 33239.72 | 23903.84 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.10M | 94.69 | 82.20 | 35.74 | 24.54 |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | 2.19 | 1.86 | 1.92 | 2.22 |
| Benitec Biopharma Inc. (BNTC)vs › | $317.09M | N/A | 995.02 | 3050.37 | 3251.65 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-05 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
